DE2213737A1 - Lh-releasing hormon mit protrahierter wirkung - Google Patents

Lh-releasing hormon mit protrahierter wirkung

Info

Publication number
DE2213737A1
DE2213737A1 DE2213737A DE2213737A DE2213737A1 DE 2213737 A1 DE2213737 A1 DE 2213737A1 DE 2213737 A DE2213737 A DE 2213737A DE 2213737 A DE2213737 A DE 2213737A DE 2213737 A1 DE2213737 A1 DE 2213737A1
Authority
DE
Germany
Prior art keywords
lrh
aqueous solution
gelatin derivative
protracted effect
releasing hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE2213737A
Other languages
German (de)
English (en)
Inventor
Rolf Dipl Chem Dr Geiger
Wolfgang Dipl Chem Dr Heptner
Richard Dr Leeb
Juergen Dr Sandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE2213737A priority Critical patent/DE2213737A1/de
Priority to NL7303709A priority patent/NL7303709A/xx
Priority to FR7309899A priority patent/FR2182882A1/fr
Priority to IL41833A priority patent/IL41833A0/xx
Priority to DD169577A priority patent/DD109305A5/xx
Priority to AU53498/73A priority patent/AU5349873A/en
Priority to ZA731985A priority patent/ZA731985B/xx
Priority to BE129120A priority patent/BE797166A/xx
Publication of DE2213737A1 publication Critical patent/DE2213737A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE2213737A 1972-03-22 1972-03-22 Lh-releasing hormon mit protrahierter wirkung Pending DE2213737A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE2213737A DE2213737A1 (de) 1972-03-22 1972-03-22 Lh-releasing hormon mit protrahierter wirkung
NL7303709A NL7303709A (cg-RX-API-DMAC7.html) 1972-03-22 1973-03-16
FR7309899A FR2182882A1 (en) 1972-03-22 1973-03-20 Luteinising hormone releasing hormone prepns with depot - effect - contg diisocyanate-crosslinked gelatin and polyphloretin pho
IL41833A IL41833A0 (en) 1972-03-22 1973-03-20 Lh-releasing hormone having a prolonged activity
DD169577A DD109305A5 (cg-RX-API-DMAC7.html) 1972-03-22 1973-03-20
AU53498/73A AU5349873A (en) 1972-03-22 1973-03-20 Lh-releasing hormone having a prolonged activity
ZA731985A ZA731985B (en) 1972-03-22 1973-03-21 Lh-releasing hormone having a prolonged activity
BE129120A BE797166A (fr) 1972-03-22 1973-03-22 Composition a base de lrh a effet prolonge et medicaments qui en contiennent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2213737A DE2213737A1 (de) 1972-03-22 1972-03-22 Lh-releasing hormon mit protrahierter wirkung

Publications (1)

Publication Number Publication Date
DE2213737A1 true DE2213737A1 (de) 1973-09-27

Family

ID=5839661

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2213737A Pending DE2213737A1 (de) 1972-03-22 1972-03-22 Lh-releasing hormon mit protrahierter wirkung

Country Status (8)

Country Link
AU (1) AU5349873A (cg-RX-API-DMAC7.html)
BE (1) BE797166A (cg-RX-API-DMAC7.html)
DD (1) DD109305A5 (cg-RX-API-DMAC7.html)
DE (1) DE2213737A1 (cg-RX-API-DMAC7.html)
FR (1) FR2182882A1 (cg-RX-API-DMAC7.html)
IL (1) IL41833A0 (cg-RX-API-DMAC7.html)
NL (1) NL7303709A (cg-RX-API-DMAC7.html)
ZA (1) ZA731985B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779072A1 (en) 1995-12-15 1997-06-18 Takeda Chemical Industries, Ltd. Production of microspheres
EP0781548A2 (en) 1995-12-15 1997-07-02 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779072A1 (en) 1995-12-15 1997-06-18 Takeda Chemical Industries, Ltd. Production of microspheres
EP0781548A2 (en) 1995-12-15 1997-07-02 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection

Also Published As

Publication number Publication date
NL7303709A (cg-RX-API-DMAC7.html) 1973-09-25
FR2182882A1 (en) 1973-12-14
AU5349873A (en) 1974-09-26
DD109305A5 (cg-RX-API-DMAC7.html) 1974-11-05
IL41833A0 (en) 1973-05-31
BE797166A (fr) 1973-09-24
ZA731985B (en) 1973-12-19

Similar Documents

Publication Publication Date Title
Pazzagli et al. Amnesic properties of scopolamine and brain acetylcholine in the rat
DE2036114C3 (de) Wäßriges Tetramisolpräparat
DE2343037A1 (de) Arzneimittel mit antidepressiver wirkung
DE3027039A1 (de) Pharmazeutischer ansatz mit einer corticosteroid-substanz
DE2830629A1 (de) Arzneimittel auf peptidbasis
DE2543214A1 (de) Nucleasebestaendiger hydrophiler komplex aus polyriboinosin-polyribocytidylsaeure und einem polylysin sowie verfahren zu seiner herstellung
DE2705514B2 (de) Nonapeptide und diese enthaltende Arzneimittel
CH637375A5 (de) Verfahren zur herstellung von tris(hydroxymethyl)-aminomethan-salzen von prostansaeuren.
DE2213737A1 (de) Lh-releasing hormon mit protrahierter wirkung
DE69013431T2 (de) Anthocyanidine zur Behandlung von Augenkrankheiten.
DE2504615C3 (de) Verfahren zur Herstellung eines Geles mit einem Gehalt an ß-Methason- 17-benzoat bzw. Fluocinolonacetonid und Neomycin
DE3852843T2 (de) Zusammensetzung mit synthetischem Aluminiumsilikat.
CH641680A5 (de) Verfahren zur herstellung injizierbarer insulinpraeparate.
EP0132595B1 (de) Tokolytisches Mittel
DE2532823C2 (de) L-Threonyl-prolyl-arginyl-lysin und dessen Verwendung
DE2104344A1 (de) Protrahiert wirkendes Sekretin-Präparat
DE1518057B2 (de) Injizierbares adrenocorticotropes hormonpraeparat mit prolongierter acthaktivitaet
DE2538843A1 (de) Wasserloeslicher pharmazeutischer komplex, verfahren zu seiner herstellung und pharmazeutische zubereitungen, worin er enthalten ist
DE2036113C3 (de) Wäßriges Tetramisolpräparat
DE437923C (de) Verfahren zur Herstellung eines Yohimbin-Brucin-Doppelsalzes
DE1960500B2 (de) Verwendung eines extraktes aus urin von traechtigen stuten zur stabilisierung von synthetischem natriumoestronsulfat
DE929665C (de) Verfahren zur Herstellung von therapeutisch wirksamen Streptomycin- und Dihydrostreptomycinsalzen
DE2550992C2 (cg-RX-API-DMAC7.html)
DE2217170A1 (de) Zinkkomplexe des lh-releasing hormons mit protrahierter wirkung und verfahren zu ihrer herstellung
DE1792271C3 (de) Blutdrucksenkendes Arzneimittel